OPTIMIZED ANTIBODIES THAT TARGET CD19

The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg³R or alters effector function as compared to the parent antibody. Also disclosed are methods of us...

Full description

Saved in:
Bibliographic Details
Main Authors Bernett, Matthew J, Richards, John O, Zhukovsky, Eugene Alexander, Lazar, Gregory Alan, Karki, Sher Bahadur, Pong, Erik WeiKing, Desjarlais, John R, Chu, Seung Yup
Format Patent
LanguageCroatian
English
Published 05.08.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

Abstract The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg³R or alters effector function as compared to the parent antibody. Also disclosed are methods of using said antibodies.
AbstractList The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg³R or alters effector function as compared to the parent antibody. Also disclosed are methods of using said antibodies.
Author Pong, Erik WeiKing
Richards, John O
Desjarlais, John R
Lazar, Gregory Alan
Karki, Sher Bahadur
Zhukovsky, Eugene Alexander
Bernett, Matthew J
Chu, Seung Yup
Author_xml – fullname: Bernett, Matthew J
– fullname: Richards, John O
– fullname: Zhukovsky, Eugene Alexander
– fullname: Lazar, Gregory Alan
– fullname: Karki, Sher Bahadur
– fullname: Pong, Erik WeiKing
– fullname: Desjarlais, John R
– fullname: Chu, Seung Yup
BookMark eNrjYmDJy89L5WRQ9Q8I8fT1jHJ1UXD0C_F08nfxdA1WCPFwDFEIcQxydw1RcHYxtORhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfEeQQFGBobGBsaGJiEhRsbEqQIAEkkmLg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate OPTIMIZIRANA ANTITIJELA USMJERENA NA CD19
ExternalDocumentID HRP20130314TT2
GroupedDBID EVB
ID FETCH-epo_espacenet_HRP20130314TT23
IEDL.DBID EVB
IngestDate Fri Jul 19 14:19:21 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Croatian
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_HRP20130314TT23
Notes Application Number: HR2013P000314T
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220805&DB=EPODOC&CC=HR&NR=P20130314T2
ParticipantIDs epo_espacenet_HRP20130314TT2
PublicationCentury 2000
PublicationDate 20220805
PublicationDateYYYYMMDD 2022-08-05
PublicationDate_xml – month: 08
  year: 2022
  text: 20220805
  day: 05
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies Xencor Inc
RelatedCompanies_xml – name: Xencor Inc
Score 3.419962
Snippet The present disclosure describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein...
SourceID epo
SourceType Open Access Repository
SubjectTerms BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Title OPTIMIZED ANTIBODIES THAT TARGET CD19
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220805&DB=EPODOC&locale=&CC=HR&NR=P20130314T2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1JS8NAFH6UKupNq2K1SkDNLZh9OQTJahSahDBK8VKyTFAELW3Ev--bIbWeehtm4M3Mg7d885YBuDGoUrZWy6K6JZV0p6klp7Y0qSqpXSm1rdm8ynWamsmz_jQzZgP4WNfC8D6hP7w5IkpUjfLecX292DxihTy3cnVXvePU131M3FDs0bGqogNkiKHvRnkWZoEYBG5SiGnh5ioL0WmKTlBf7zA_mjXaj158Vpay-G9T4kPYzZHcZ3cEg7flCPaD9ddrI9ib9hFvHPbCtzqG2ywnqGpeo1DwUvLoZ8yVE0jiEYF4xUNEhCBUnBO4jiMSJBLuN_-73TwpNmcjqnYKQ8T99AyE0my0SmkbS5apjiigrPTSsBpEBLYpt3Y7hsk2Sufbly_ggPGL57IZExh2y296ifa1q644X34BrL96rw
link.rule.ids 230,309,786,891,25594,76903
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1JS8NAFH6UKtabVsVq1YCaWzB70kOQrKbaLIRRipeQFUXQ0kb8-74MqfXU2zADb2YevOWbtwzAjVIJWa3VbVQ3qzh5UhbcpNAkLs8qPRcKXdJplWsQqv6z_DhX5j34WNfC0D6hP7Q5IkpUgfLeUH292DxiOTS3cnWXv-PU171HDIft0LEoogOksI5luHHkRDZr24afsGFixGIbopMEmaC-3tEQE1Ks9GK1ZSmL_zbFO4DdGMl9NofQe1sOYWCvv14bwl7QRbxx2Anf6ghuo5igqnl1HcYMydSKWleOIb5JGGImDy5hbEeYHMO15xLb53C_9O92qZ9szkZE6QT6iPurU2AytZRyoS41nq9kRAFZLmeKViIi0FW-1usRjLdROtu-fAUDnwSzdDYNn85hv-UdzWtTxtBvlt_VBdraJr-kPPoFjgV9mQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=OPTIMIZED+ANTIBODIES+THAT+TARGET+CD19&rft.inventor=Bernett%2C+Matthew+J&rft.inventor=Richards%2C+John+O&rft.inventor=Zhukovsky%2C+Eugene+Alexander&rft.inventor=Lazar%2C+Gregory+Alan&rft.inventor=Karki%2C+Sher+Bahadur&rft.inventor=Pong%2C+Erik+WeiKing&rft.inventor=Desjarlais%2C+John+R&rft.inventor=Chu%2C+Seung+Yup&rft.date=2022-08-05&rft.externalDBID=T2&rft.externalDocID=HRP20130314TT2